Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

347 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Specific activity of cyclin-dependent kinase I is a new potential predictor of tumour recurrence in stage II colon cancer.
Zeestraten EC, Maak M, Shibayama M, Schuster T, Nitsche U, Matsushima T, Nakayama S, Gohda K, Friess H, van de Velde CJ, Ishihara H, Rosenberg R, Kuppen PJ, Janssen KP. Zeestraten EC, et al. Among authors: shibayama m. Br J Cancer. 2012 Jan 3;106(1):133-40. doi: 10.1038/bjc.2011.504. Epub 2011 Nov 22. Br J Cancer. 2012. PMID: 22108518 Free PMC article.
Validation study of the prognostic value of cyclin-dependent kinase (CDK)-based risk in Caucasian breast cancer patients.
van Nes JG, Smit VT, Putter H, Kuppen PJ, Kim SJ, Daito M, Ding J, Shibayama M, Numada S, Gohda K, Matsushima T, Ishihara H, Noguchi S, van de Velde CJ. van Nes JG, et al. Among authors: shibayama m. Br J Cancer. 2009 Feb 10;100(3):494-500. doi: 10.1038/sj.bjc.6604870. Epub 2009 Jan 20. Br J Cancer. 2009. PMID: 19156146 Free PMC article.
The prognostic value of apoptotic and proliferative markers in breast cancer.
Engels CC, Ruberta F, de Kruijf EM, van Pelt GW, Smit VT, Liefers GJ, Matsushima T, Shibayama M, Ishihara H, van de Velde CJ, Kuppen PJ. Engels CC, et al. Among authors: shibayama m. Breast Cancer Res Treat. 2013 Nov;142(2):323-39. doi: 10.1007/s10549-013-2748-y. Epub 2013 Nov 6. Breast Cancer Res Treat. 2013. PMID: 24194179
Recurrence risk score based on the specific activity of CDK1 and CDK2 predicts response to neoadjuvant paclitaxel followed by 5-fluorouracil, epirubicin and cyclophosphamide in breast cancers.
Kim SJ, Nakayama S, Shimazu K, Tamaki Y, Akazawa K, Tsukamoto F, Torikoshi Y, Matsushima T, Shibayama M, Ishihara H, Noguchi S. Kim SJ, et al. Among authors: shibayama m. Ann Oncol. 2012 Apr;23(4):891-7. doi: 10.1093/annonc/mdr340. Epub 2011 Aug 4. Ann Oncol. 2012. PMID: 21821547 Free article. Clinical Trial.
347 results